162 related articles for article (PubMed ID: 22971818)
1. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.
Poirier JT; Reddy PS; Idamakanti N; Li SS; Stump KL; Burroughs KD; Hallenbeck PL; Rudin CM
J Gen Virol; 2012 Dec; 93(Pt 12):2606-2613. PubMed ID: 22971818
[TBL] [Abstract][Full Text] [Related]
2. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
Reddy PS; Burroughs KD; Hales LM; Ganesh S; Jones BH; Idamakanti N; Hay C; Li SS; Skele KL; Vasko AJ; Yang J; Watkins DN; Rudin CM; Hallenbeck PL
J Natl Cancer Inst; 2007 Nov; 99(21):1623-33. PubMed ID: 17971529
[TBL] [Abstract][Full Text] [Related]
3. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.
Miles LA; Burga LN; Gardner EE; Bostina M; Poirier JT; Rudin CM
J Clin Invest; 2017 Aug; 127(8):2957-2967. PubMed ID: 28650343
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
Rudin CM; Poirier JT; Senzer NN; Stephenson J; Loesch D; Burroughs KD; Reddy PS; Hann CL; Hallenbeck PL
Clin Cancer Res; 2011 Feb; 17(4):888-95. PubMed ID: 21304001
[TBL] [Abstract][Full Text] [Related]
5. A Structure-Guided Genetic Modification Strategy: Developing Seneca Valley Virus Therapy against Nonsensitive Nonsmall Cell Lung Carcinoma.
Zhao Z; Cao L; Sun Z; Liu W; Li X; Fang K; Shang X; Hu J; Chen H; Lou Z; Qian P
J Virol; 2023 May; 97(5):e0045923. PubMed ID: 37097154
[TBL] [Abstract][Full Text] [Related]
6. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
Liu Z; Zhao X; Mao H; Baxter PA; Huang Y; Yu L; Wadhwa L; Su JM; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Hurwitz RL; Lau CC; Chintagumpala M; Blaney SM; Li XN
Neuro Oncol; 2013 Sep; 15(9):1173-85. PubMed ID: 23658322
[TBL] [Abstract][Full Text] [Related]
7. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.
Poirier JT; Dobromilskaya I; Moriarty WF; Peacock CD; Hann CL; Rudin CM
J Natl Cancer Inst; 2013 Jul; 105(14):1059-65. PubMed ID: 23739064
[TBL] [Abstract][Full Text] [Related]
8. Recovery of duck hepatitis A virus 3 from a stable full-length infectious cDNA clone.
Pan M; Yang X; Du J; Zhou L; Ge X; Guo X; Liu J; Zhang D; Yang H
Virus Res; 2011 Sep; 160(1-2):439-43. PubMed ID: 21801768
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a full-length cDNA infectious clone of emerging porcine Senecavirus A.
Chen Z; Yuan F; Li Y; Shang P; Schroeder R; Lechtenberg K; Henningson J; Hause B; Bai J; Rowland RRR; Clavijo A; Fang Y
Virology; 2016 Oct; 497():111-124. PubMed ID: 27459668
[TBL] [Abstract][Full Text] [Related]
10. Development of infectious transcripts from full-length and GFP-tagged cDNA clones of Pepper mottle virus and stable systemic expression of GFP in tobacco and pepper.
Lee MY; Song YS; Ryu KH
Virus Res; 2011 Feb; 155(2):487-94. PubMed ID: 21167886
[TBL] [Abstract][Full Text] [Related]
11. Infectious simian varicella virus expressing the green fluorescent protein.
Mahalingam R; Wellish M; White T; Soike K; Cohrs R; Kleinschmidt-DeMasters BK; Gilden DH
J Neurovirol; 1998 Aug; 4(4):438-44. PubMed ID: 9718136
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Seneca Valley Virus: past perspectives and future directions.
Burke MJ
Oncolytic Virother; 2016; 5():81-9. PubMed ID: 27660749
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein.
Engel-Herbert I; Werner O; Teifke JP; Mebatsion T; Mettenleiter TC; Römer-Oberdörfer A
J Virol Methods; 2003 Mar; 108(1):19-28. PubMed ID: 12565150
[TBL] [Abstract][Full Text] [Related]
14. Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.
Venkataraman S; Reddy SP; Loo J; Idamakanti N; Hallenbeck PL; Reddy VS
Structure; 2008 Oct; 16(10):1555-61. PubMed ID: 18940610
[TBL] [Abstract][Full Text] [Related]
15. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus.
Jayawardena N; Burga LN; Easingwood RA; Takizawa Y; Wolf M; Bostina M
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10934-E10940. PubMed ID: 30381454
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Assessment of the Health Risk for Livestock When Animal Viruses Are Applied in Human Oncolytic Therapy: A Case Study for Seneca Valley Virus.
Schijven J; Brizee S; Teunis P; de Vos C; Eblé P; Rutjes S
Risk Anal; 2019 May; 39(5):982-991. PubMed ID: 30395685
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
Virol J; 2014 May; 11():84. PubMed ID: 24885546
[TBL] [Abstract][Full Text] [Related]
19. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
[TBL] [Abstract][Full Text] [Related]
20. Rescue of NanoLuc luciferase-expressing Senecavirus A with oncolytic activity.
Liu F; Wang Q; Huang Y; Wang N; Shan H
Virus Res; 2021 Jan; 292():198232. PubMed ID: 33207264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]